Details for New Drug Application (NDA): 203634
✉ Email this page to a colleague
NDA 203634 describes UCERIS, which is a drug marketed by Salix and is included in two NDAs. It is available from three suppliers. There are five patents protecting this drug and one Paragraph IV challenge. Additional details are available on the UCERIS profile page.
The generic ingredient in UCERIS is budesonide. There are twenty-two drug master file entries for this compound. Forty-two suppliers are listed for this compound. Additional details are available on the budesonide profile page.
The generic ingredient in UCERIS is budesonide. There are twenty-two drug master file entries for this compound. Forty-two suppliers are listed for this compound. Additional details are available on the budesonide profile page.
Summary for 203634
| Tradename: | UCERIS |
| Applicant: | Salix |
| Ingredient: | budesonide |
| Patents: | 5 |
Pharmacology for NDA: 203634
| Mechanism of Action | Corticosteroid Hormone Receptor Agonists |
Medical Subject Heading (MeSH) Categories for 203634
Suppliers and Packaging for NDA: 203634
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| UCERIS | budesonide | TABLET, EXTENDED RELEASE;ORAL | 203634 | NDA | Santarus Inc. | 68012-309 | 68012-309-01 | 2 TABLET, EXTENDED RELEASE in 1 BLISTER PACK (68012-309-01) |
| UCERIS | budesonide | TABLET, EXTENDED RELEASE;ORAL | 203634 | NDA | Santarus Inc. | 68012-309 | 68012-309-02 | 2 TABLET, EXTENDED RELEASE in 1 BLISTER PACK (68012-309-02) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET, EXTENDED RELEASE;ORAL | Strength | 9MG | ||||
| Approval Date: | Jan 14, 2013 | TE: | AB | RLD: | Yes | ||||
| Patent: | ⤷ Get Started Free | Patent Expiration: | Sep 7, 2031 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
| Patent: | ⤷ Get Started Free | Patent Expiration: | Sep 7, 2031 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
| Patent: | ⤷ Get Started Free | Patent Expiration: | Sep 7, 2031 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Expired US Patents for NDA 203634
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Salix | UCERIS | budesonide | TABLET, EXTENDED RELEASE;ORAL | 203634-001 | Jan 14, 2013 | ⤷ Get Started Free | ⤷ Get Started Free |
| Salix | UCERIS | budesonide | TABLET, EXTENDED RELEASE;ORAL | 203634-001 | Jan 14, 2013 | ⤷ Get Started Free | ⤷ Get Started Free |
| Salix | UCERIS | budesonide | TABLET, EXTENDED RELEASE;ORAL | 203634-001 | Jan 14, 2013 | ⤷ Get Started Free | ⤷ Get Started Free |
| Salix | UCERIS | budesonide | TABLET, EXTENDED RELEASE;ORAL | 203634-001 | Jan 14, 2013 | ⤷ Get Started Free | ⤷ Get Started Free |
| Salix | UCERIS | budesonide | TABLET, EXTENDED RELEASE;ORAL | 203634-001 | Jan 14, 2013 | ⤷ Get Started Free | ⤷ Get Started Free |
| Salix | UCERIS | budesonide | TABLET, EXTENDED RELEASE;ORAL | 203634-001 | Jan 14, 2013 | ⤷ Get Started Free | ⤷ Get Started Free |
| Salix | UCERIS | budesonide | TABLET, EXTENDED RELEASE;ORAL | 203634-001 | Jan 14, 2013 | ⤷ Get Started Free | ⤷ Get Started Free |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription
